Aflibercept 16-Week Dosing Regimen for Diabetic Retinopathy Under Review
The sBLA is supported by data from the phase 3 PANORAMA trial and the NIH-sponsored Protocol W trial.
Category: Miscellaneous Ocular Agents
Visomitin Gets Orphan Drug Status for Leber Hereditary Optic Neuropathy
The Food and Drug Administration (FDA) has granted Orphan Drug designation to visomitin for the treatment of Leber hereditary optic neuropathy (LHON), a rare genetic disease characterized by the degeneration of retinal ganglion cells that…
Tebentafusp Gets Priority Review for Metastatic Uveal Melanoma
The Food and Drug Administration has accepted for Priority Review the Biologics License Application for tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma. Tebentafusp is a novel bispecific protein comprised…